CRISPR-Modified Cells Have Been Used in a Person for the First Time
A clinical trial in China aims to see if engineered immune cells can fight off late-stage lung cancer.
A team of Chinese scientists has become the first to test CRISPR gene-edited cells in a human. The researchers, from Sichuan University in Chengdu, injected the cells into a patient with advanced lung cancer.
The experiment marks the beginning of an early stage clinical trial designed to test the safety of using CRISPR—a cheap, easy, and reasonably accurate way to edit DNA in living cells—to disable a gene in T-cells that suppresses immune response. According to Nature, which first broke the news of the trial, the injection went “smoothly,” and 10 patients are expected to receive injections.
Genetically modifying immune cells to turn them into cancer-hunters is a technology that’s now a few years old. Treatments remain experimental, though, and because their side effects can be fatal, messing with a patient’s immune system on the genetic level is only done for the sickest patients suffering from a limited subset of cancers.
But those techniques—in which immune cells are harvested from a patient, modified, and then returned to their body—involve adding a gene to give the cells a receptor that turns them into cancer-killers. Using CRISPR allowed the researchers to turn off a gene that codes for the PD-1 protein, which prevents the immune system from attacking cancer.
Human trials of CRISPR have been proposed in the U.S., including a scheme to knock out the gene behind PD-1—but so far none have been carried out.
Carl June, a researcher from the University of Pennsylvania who hopes to carry out some of the first such experiments in America, told Nature that he thinks the news could “trigger ‘Sputnik 2.0,’ a biomedical duel on progress between China and the United States.”
Keep up with the latest in CRISPR at EmTech MIT.
Discover where tech, business, and culture converge.
September 17-19, 2019
MIT Media Lab